Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Terminated 1Suspended 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Neoplasms 2Neoplasm Metastasis 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Pancreatic Neoplasms 1Gallbladder Neoplasms 1Digestive System Neoplasms 1Adenocarcinoma 1

Interventions

Fluorouracil 98Oxaliplatin 94Leucovorin 86Irinotecan 70Gemcitabine 66Bevacizumab 62Capecitabine 60Cetuximab 42pembrolizumab 37Cisplatin 30Nivolumab 25Drug Therapy 25130-nm albumin-bound paclitaxel 22Specimen Handling 20Folfox protocol 20Panitumumab 19Paclitaxel 19Magnetic Resonance Spectroscopy 18Albumin-Bound Paclitaxel 17Biopsy 16IFL protocol 15Floxuridine 15Docetaxel 15Cyclophosphamide 15Sorafenib 14regorafenib 12Erlotinib Hydrochloride 12aflibercept 11Radiofrequency Ablation 11fludarabine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × NUC-1031 × Gastrointestinal × Clear all
NCT04163900 2023-05-24

Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer

NuCana plc

Phase 3 Terminated
773 enrolled 15 charts
Gastrointestinal

Adenocarcinoma, Biliary Tract Neoplasms, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms, Cholangiocarcinoma

NCT03610100 2019-10-29

ACELARATE

The Clatterbridge Cancer Centre NHS Foundation Trust

Phase 2/3 Suspended
328 enrolled
Gastrointestinal

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡